MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

TransMedics Group Inc

Open

BrancheGesundheitswesen

91.25 -2.72

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

90.97

Max

95.02

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.6M

6.9M

Verkäufe

13M

122M

KGV

Branchendurchschnitt

81.981

57.333

EPS

0.19

Gewinnspanne

5.638

Angestellte

728

EBITDA

3.2M

16M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+8.4% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

8. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

397M

3B

Vorheriger Eröffnungskurs

93.97

Vorheriger Schlusskurs

91.25

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

TransMedics Group Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Sept. 2024, 03:29 UTC

Top News

Dow Jones Futures: Meta, Apple, Tesla Lead New Buys In Big Rally. Pay Attention To This Key Shift. -- IBD

Peer-Vergleich

Kursveränderung

TransMedics Group Inc Prognose

Kursziel

By TipRanks

8.4% Vorteil

12-Monats-Prognose

Durchschnitt 100 USD  8.4%

Hoch 125 USD

Tief 80 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für TransMedics Group Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

5

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

88.48 / N/AUnterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Very Strong Bullish Evidence

Langfristig

Weak Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.